Recent advances in applying mass spectrometry and systems biology to determine brain dynamics

Abstract

Neurological disorders encompass various pathologies which disrupt normal brain physiology and function. Poor understanding of their underlying molecular mechanisms and their societal burden argues for the necessity of novel prevention strategies, early diagnostic techniques and alternative treatment options to reduce the scale of their expected increase. Areas covered: This review scrutinizes mass spectrometry based approaches used to investigate brain dynamics in various conditions, including neurodegenerative and neuropsychiatric disorders. Different proteomics workflows for isolation/enrichment of specific cell populations or brain regions, sample processing; mass spectrometry technologies, for differential proteome quantitation, analysis of post-translational modifications and imaging approaches in the brain are critically deliberated. Future directions, including analysis of cellular sub-compartments, targeted MS platforms (selected/parallel reaction monitoring) and use of mass cytometry are also discussed. Expert commentary: Here, we summarize and evaluate current mass spectrometry based approaches for determining brain dynamics in health and diseases states, with a focus on neurological disorders. Furthermore, we provide insight on current trends and new MS technologies with potential to improve this analysis.

Normal Mouse Brain Proteome II: Analysis of Brain Regions by High-resolution Mass Spectrometry

“…In the past two decades, although human brain tissue preparations have been shown to be suitable for in vitro or in vivo metabolic, anatomical and functional studies, due to ethical issues, as well as the necessity of extended normal and abnormal subject comparisons, experimental animal studies still remain central to neurochemistry, neuroanatomy and neuroproteomics. Although huge proteomics studies on human brain were performed in abnormal conditions, such as Alzheimer's disease (6), Parkinson's disease (7) and brain tumors (8)(9)(10), little work has been carried out on the proteomic analysis of the normal brain (11,12). The limitations of these analyses are due to ethical issues as well as the necessity for extended normal and abnormal subject comparisons.…”

Angiotensin-(1-7) and Mas receptor in the brain

“…This limitation in antibody specificity has raised the need to validate each antibody [39]. Over the last years, mass spectrometry (MS) has arisen as an important alternative for the development of assays designed to specifically identify Ang peptides [40]. More recently, a new technology was developed by coupling a laboratory-built capillary electrophoresis nanoelectrospray ionization platform to a high-resolution mass spectrometer, allowing the quantification of Ang peptides with high sensitivity [37].…”

The Discovery of Clinically Applicable Biomarkers for Bipolar Disorder: A Review of Candidate and Proteomic Approaches

“…However, this goal can only be achieved through interdisciplinary joint efforts which require collaboration from biochemists, biologists, molecular genetic experts, statisticians, alongside clinicians. 84…”